Bloom Burton Issues Pessimistic Outlook for TSE:MDP Earnings

Medexus Pharmaceuticals Inc. (TSE:MDP) – Bloom Burton dropped their Q4 2025 earnings per share (EPS) estimates for shares of Medexus Pharmaceuticals in a research report issued to clients and investors on Thursday, January 23rd. Bloom Burton analyst D. Martin now anticipates that the company will post earnings of ($0.01) per share for the quarter, down from their previous forecast of $0.01. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share.

Several other equities research analysts have also issued reports on MDP. Raymond James raised shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price objective for the company in a research report on Wednesday, January 8th. Alliance Global Partners upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a report on Monday, December 23rd. Leede Financial raised Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday. Ventum Cap Mkts upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 17th. Finally, Stifel Nicolaus boosted their price target on Medexus Pharmaceuticals from C$4.15 to C$4.50 in a research report on Tuesday, January 14th. One research analyst has rated the stock with a buy rating and five have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Strong Buy” and a consensus price target of C$5.58.

Medexus Pharmaceuticals Stock Performance

MDP opened at C$4.92 on Friday. The company has a market cap of C$120.69 million, a PE ratio of 98.40 and a beta of 1.96. Medexus Pharmaceuticals has a 1 year low of C$1.47 and a 1 year high of C$5.56. The firm has a 50 day moving average price of C$3.25 and a 200 day moving average price of C$2.72.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.